## Jacob M Hooker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6890646/publications.pdf

Version: 2024-02-01

190 papers 9,779 citations

54 h-index 90 g-index

206 all docs

206 docs citations

206 times ranked 12105 citing authors

#	Article	IF	CITATIONS
1	Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain. JAMA - Journal of the American Medical Association, 2009, 301, 1148.	3.8	466
2	A Fluoride-Derived Electrophilic Late-Stage Fluorination Reagent for PET Imaging. Science, 2011, 334, 639-642.	6.0	384
3	Evidence for brain glial activation in chronic pain patients. Brain, 2015, 138, 604-615.	3.7	372
4	Interior Surface Modification of Bacteriophage MS2. Journal of the American Chemical Society, 2004, 126, 3718-3719.	6.6	313
5	Nickel-Mediated Oxidative Fluorination for PET with Aqueous [ <sup>18</sup> F] Fluoride. Journal of the American Chemical Society, 2012, 134, 17456-17458.	6.6	260
6	Concerted nucleophilic aromatic substitution with 19Fâ° and 18Fâ°. Nature, 2016, 534, 369-373.	13.7	225
7	Late Stage Benzylic C–H Fluorination with [ <sup>18</sup> F]Fluoride for PET Imaging. Journal of the American Chemical Society, 2014, 136, 6842-6845.	6.6	206
8	Brain glial activation in fibromyalgia $\hat{a} \in A$ multi-site positron emission tomography investigation. Brain, Behavior, and Immunity, 2019, 75, 72-83.	2.0	186
9	Dual-Surface-Modified Bacteriophage MS2 as an Ideal Scaffold for a Viral Capsid-Based Drug Delivery System. Bioconjugate Chemistry, 2007, 18, 1140-1147.	1.8	184
10	Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [11C]-PBR28. NeuroImage: Clinical, 2015, 7, 409-414.	1.4	176
11	High Relaxivity Gadolinium Hydroxypyridonateâ^'Viral Capsid Conjugates:  Nanosized MRI Contrast Agents <sup>1</sup> . Journal of the American Chemical Society, 2008, 130, 2546-2552.	6.6	165
12	In Vivo Imaging of Human Neuroinflammation. ACS Chemical Neuroscience, 2016, 7, 470-483.	1.7	165
13	Neuroinflammatory component of gray matter pathology in multiple sclerosis. Annals of Neurology, 2016, 80, 776-790.	2.8	150
14	Oneâ€Pot, Direct Incorporation of [ <sup>11</sup> C]CO <sub>2</sub> into Carbamates. Angewandte Chemie - International Edition, 2009, 48, 3482-3485.	7.2	138
15	Magnetic Resonance Contrast Agents from Viral Capsid Shells:  A Comparison of Exterior and Interior Cargo Strategies. Nano Letters, 2007, 7, 2207-2210.	4.5	135
16	Disruption of thalamic functional connectivity is a neural correlate of dexmedetomidine-induced unconsciousness. ELife, 2014, 3, e04499.	2.8	135
17	Targeted Fluorination with the Fluoride Ion by Manganeseâ€Catalyzed Decarboxylation. Angewandte Chemie - International Edition, 2015, 54, 5241-5245.	7.2	129
18	Dynamic functional imaging of brain glucose utilization using fPET-FDG. NeuroImage, 2014, 100, 192-199.	2.1	123

#	Article	IF	CITATIONS
19	Polyglucose nanoparticles with renal elimination and macrophage avidity facilitate PET imaging in ischaemic heart disease. Nature Communications, 2017, 8, 14064.	5.8	118
20	A Selective HDAC $1/2$ Inhibitor Modulates Chromatin and Gene Expression in Brain and Alters Mouse Behavior in Two Mood-Related Tests. PLoS ONE, 2013, 8, e71323.	1.1	118
21	Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11169-11174.	3.3	112
22	A Philosophy for CNS Radiotracer Design. Accounts of Chemical Research, 2014, 47, 3127-3134.	7.6	109
23	Neuroinflammation of the spinal cord and nerve roots in chronic radicular pain patients. Pain, 2018, 159, 968-977.	2.0	109
24	Brain-Penetrant LSD1 Inhibitors Can Block Memory Consolidation. ACS Chemical Neuroscience, 2012, 3, 120-128.	1.7	104
25	<sup>11</sup> Cî€O bonds made easily for positron emission tomography radiopharmaceuticals. Chemical Society Reviews, 2016, 45, 4708-4726.	18.7	98
26	Dopamine in the medial amygdala network mediates human bonding. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2361-2366.	3.3	96
27	11CO2 fixation: a renaissance in PET radiochemistry. Chemical Communications, 2013, 49, 5621.	2.2	92
28	Combination therapy: Histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Letters, 2013, 329, 1-8.	3.2	87
29	Application of Palladium-Mediated 18F-Fluorination to PET Radiotracer Development: Overcoming Hurdles to Translation. PLoS ONE, 2013, 8, e59187.	1.1	87
30	Histone Deacetylase Inhibitor MS-275 Exhibits Poor Brain Penetration: Pharmacokinetic Studies of [ <sup>11</sup> C]MS-275 using Positron Emission Tomography. ACS Chemical Neuroscience, 2010, 1, 65-73.	1.7	85
31	Toward an immune-mediated subtype of autism spectrum disorder. Brain Research, 2015, 1617, 72-92.	1.1	84
32	Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis. Neurology, 2016, 87, 2554-2561.	1.5	83
33	Insights into neuroepigenetics through human histone deacetylase PET imaging. Science Translational Medicine, 2016, 8, 351ra106.	5.8	83
34	Imaging of neuroinflammation in migraine with aura. Neurology, 2019, 92, e2038-e2050.	1.5	83
35	Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET. Nuclear Medicine and Biology, 2013, 40, 912-918.	0.3	82
36	In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs. Journal of Medicinal Chemistry, 2014, 57, 7999-8009.	2.9	82

#	Article	IF	Citations
37	Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans. Neurolmage, 2008, 41, 1044-1050.	2.1	79
38	An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in $\hat{l}^2$ -Cell Protection. ACS Chemical Biology, 2016, 11, 363-374.	1.6	78
39	In vivo imaging of adult human hippocampal neurogenesis: progress, pitfalls and promise. Molecular Psychiatry, 2013, 18, 404-416.	4.1	77
40	Site-selective <sup>18</sup> F fluorination of unactivated C–H bonds mediated by a manganese porphyrin. Chemical Science, 2018, 9, 1168-1172.	3.7	76
41	Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity. Journal of Medicinal Chemistry, 2018, 61, 8054-8060.	2.9	76
42	Integrated magnetic resonance imaging and [ <sup>11</sup> C]â€PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Annals of Neurology, 2018, 83, 1186-1197.	2.8	75
43	In Vivo Photoactivation Without "Light― Use of Cherenkov Radiation to Overcome the Penetration Limit of Light. Molecular Imaging and Biology, 2012, 14, 156-162.	1.3	74
44	A systematic review of molecular imaging (PET and SPECT) in autism spectrum disorder: Current state and future research opportunities. Neuroscience and Biobehavioral Reviews, 2015, 52, 56-73.	2.9	74
45	<sup>18</sup> F-Deoxyfluorination of Phenols via Ru π-Complexes. ACS Central Science, 2017, 3, 944-948.	5.3	74
46	Modification of Aniline Containing Proteins Using an Oxidative Coupling Strategy. Journal of the American Chemical Society, 2006, 128, 15558-15559.	6.6	73
47	Bridging the gaps in 18F PET tracer development. Nature Chemistry, 2017, 9, 1-3.	6.6	71
48	Virtually Instantaneous, Room-Temperature [ $<$ sup $>$ 11 $<$ /sup $>$ C]-Cyanation Using Biaryl Phosphine Pd(0) Complexes. Journal of the American Chemical Society, 2015, 137, 648-651.	6.6	68
49	Radiosynthesis and Bioimaging of the Tuberculosis Chemotherapeutics Isoniazid, Rifampicin and Pyrazinamide in Baboons. Journal of Medicinal Chemistry, 2010, 53, 2882-2891.	2.9	66
50	Direct <sup>11</sup> CN-Labeling of Unprotected Peptides via Palladium-Mediated Sequential Cross-Coupling Reactions. Journal of the American Chemical Society, 2017, 139, 7152-7155.	6.6	65
51	Rapid Chemoselective Bioconjugation through Oxidative Coupling of Anilines and Aminophenols. Journal of the American Chemical Society, 2011, 133, 16398-16401.	6.6	60
52	Noninvasive Determination of 2-[ <sup>18</sup> F]-Fluoroisonicotinic Acid Hydrazide Pharmacokinetics by Positron Emission Tomography in Mycobacterium tuberculosis-Infected Mice. Antimicrobial Agents and Chemotherapy, 2012, 56, 6284-6290.	1.4	60
53	Imaging Evaluation of 5HT <sub>2C</sub> Agonists, [ <sup>11</sup> C]WAY-163909 and [ <sup>11</sup> C]Vabicaserin, Formed by Pictet–Spengler Cyclization. Journal of Medicinal Chemistry, 2014, 57, 1488-1494.	2.9	60
54	HDAC6 Brain Mapping with [ <sup>18</sup> F]Bavarostat Enabled by a Ru-Mediated Deoxyfluorination. ACS Central Science, 2017, 3, 1006-1014.	5.3	60

#	Article	IF	CITATIONS
55	Neuroinflammation in Huntington's Disease: New Insights with <sup>11</sup> C-PBR28 PET/MRI. ACS Chemical Neuroscience, 2018, 9, 2563-2571.	1.7	60
56	Extraâ€Axial Inflammatory Signal in Parameninges in Migraine with Visual Aura. Annals of Neurology, 2020, 87, 939-949.	2.8	60
57	Simultaneous fMRI–PET of the opioidergic pain system in human brain. Neurolmage, 2014, 102, 275-282.	2.1	59
58	Dopamine D <sub>1</sub> signaling organizes network dynamics underlying working memory. Science Advances, 2016, 2, e1501672.	4.7	59
59	Imaging Agonist-Induced D2/D3 Receptor Desensitization and Internalization In Vivo with PET/fMRI. Neuropsychopharmacology, 2016, 41, 1427-1436.	2.8	59
60	A receptor-based model for dopamine-induced fMRI signal. NeuroImage, 2013, 75, 46-57.	2.1	57
61	Synthesis and Imaging Validation of [18F]MDL100907 Enabled by Ni-Mediated Fluorination. ACS Chemical Neuroscience, 2014, 5, 611-615.	1.7	57
62	A Transmetalation Reaction Enables the Synthesis of [18F]5-Fluorouracil from [18F]Fluoride for Human PET Imaging. Organometallics, 2016, 35, 1008-1014.	1.1	57
63	PET neuroimaging reveals histone deacetylase dysregulation in schizophrenia. Journal of Clinical Investigation, 2018, 129, 364-372.	3.9	57
64	Genome-free Viral Capsids as Carriers for Positron Emission Tomography Radiolabels. Molecular Imaging and Biology, 2008, 10, 182-191.	1.3	54
65	A Simple, Rapid Method for the Preparation of [ $<$ sup $>$ 11 $<$ /sup $>$ C]Formaldehyde. Angewandte Chemie - International Edition, 2008, 47, 5989-5992.	7.2	52
66	Image-Guided Synthesis Reveals Potent Blood-Brain Barrier Permeable Histone Deacetylase Inhibitors. ACS Chemical Neuroscience, 2014, 5, 588-596.	1.7	51
67	Evaluation of 6-([18F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brain. Nuclear Medicine and Biology, 2009, 36, 247-258.	0.3	48
68	Timeâ€Dependent Diaryl Ether Inhibitors of InhA: Structure–Activity Relationship Studies of Enzyme Inhibition, Antibacterial Activity, and in vivo Efficacy. ChemMedChem, 2014, 9, 776-791.	1.6	48
69	Human Positron Emission Tomography Neuroimaging. Annual Review of Biomedical Engineering, 2019, 21, 551-581.	5.7	48
70	Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. Clinical Cancer Research, 2020, 26, 206-212.	3.2	48
71	Kinetic Analysis and Quantification of [ $<$ sup $>$ 11 $<$ /sup $>$ C]Martinostat for in Vivo HDAC Imaging of the Brain. ACS Chemical Neuroscience, 2015, 6, 708-715.	1.7	46
72	Integrated imaging of [11C]-PBR28 PET, MR diffusion and magnetic resonance spectroscopy 1H-MRS in amyotrophic lateral sclerosis. Neurolmage: Clinical, 2018, 20, 357-364.	1.4	45

#	Article	IF	CITATIONS
73	Noninvasive Assessment of Losartan-Induced Increase in Functional Microvasculature and Drug Delivery in Pancreatic Ductal Adenocarcinoma. Translational Oncology, 2016, 9, 431-437.	1.7	42
74	Expression of <i>HDAC2</i> but Not <i>HDAC1</i> Transcript Is Reduced in Dorsolateral Prefrontal Cortex of Patients with Schizophrenia. ACS Chemical Neuroscience, 2017, 8, 662-668.	1.7	42
75	[ <sup>11</sup> C]Cyanation of arylboronic acids in aqueous solutions. Chemical Communications, 2017, 53, 6597-6600.	2.2	41
76	Visualizing epigenetics: Current advances and advantages in HDAC PET imaging techniques. Neuroscience, 2014, 264, 186-197.	1.1	39
77	Synthesis of [ <sup>11</sup> C]Bexarotene by Cu-Mediated [ <sup>11</sup> C]Carbon Dioxide Fixation and Preliminary PET Imaging. ACS Medicinal Chemistry Letters, 2014, 5, 668-672.	1.3	39
78	Nicotine Blocks Brain Estrogen Synthase (Aromatase): In Vivo Positron Emission Tomography Studies in Female Baboons. Biological Psychiatry, 2010, 67, 774-777.	0.7	37
79	Salvinorin A and derivatives: Protection from metabolism does not prolong short-term, whole-brain residence. Neuropharmacology, 2009, 57, 386-391.	2.0	36
80	PET Imaging Demonstrates Histone Deacetylase Target Engagement and Clarifies Brain Penetrance of Known and Novel Small Molecule Inhibitors in Rat. ACS Chemical Neuroscience, 2014, 5, 1055-1062.	1.7	36
81	Neuroepigenetic signatures of age and sex in the living human brain. Nature Communications, 2019, 10, 2945.	5.8	36
82	Solubilization and stabilization of bacteriophage MS2 in organic solvents. Biotechnology and Bioengineering, 2007, 97, 224-234.	1.7	35
83	Modular strategies for PET imaging agents. Current Opinion in Chemical Biology, 2010, 14, 105-111.	2.8	35
84	[11C]PBR28 MR–PET imaging reveals lower regional brain expression of translocator protein (TSPO) in young adult males with autism spectrum disorder. Molecular Psychiatry, 2021, 26, 1659-1669.	4.1	35
85	Cue-Induced Dopamine Release Predicts Cocaine Preference: Positron Emission Tomography Studies in Freely Moving Rodents. Journal of Neuroscience, 2009, 29, 6176-6185.	1.7	34
86	A Novel Radiotracer for Imaging Monoacylglycerol Lipase in the Brain Using Positron Emission Tomography. ACS Chemical Neuroscience, 2016, 7, 484-489.	1.7	34
87	Amylin receptor ligands reduce the pathological cascade of Alzheimer's disease. Neuropharmacology, 2017, 119, 170-181.	2.0	34
88	A simultaneous [11C]raclopride positron emission tomography and functional magnetic resonance imaging investigation of striatal dopamine binding in autism. Translational Psychiatry, 2021, 11, 33.	2.4	33
89	PET/MRI in the Presence of Metal Implants: Completion of the Attenuation Map from PET Emission Data. Journal of Nuclear Medicine, 2017, 58, 840-845.	2.8	32
90	Pseudoreference Regions for Glial Imaging with $\langle \sup 11 \langle \sup C$ -PBR28: Investigation in 2 Clinical Cohorts. Journal of Nuclear Medicine, 2018, 59, 107-114.	2.8	32

#	Article	IF	CITATIONS
91	Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6. Journal of Medicinal Chemistry, 2020, 63, 295-308.	2.9	32
92	Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brain. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6700-6705.	1.0	31
93	Enzyme-catalyzed hydrolysis of poly(ethylene terephthalate) cyclic trimer. Journal of Applied Polymer Science, 2003, 89, 2545-2552.	1.3	30
94	Imaging of glia activation in people with primary lateral sclerosis. NeuroImage: Clinical, 2018, 17, 347-353.	1.4	29
95	A pilot trial of RNS60 in amyotrophic lateral sclerosis. Muscle and Nerve, 2019, 59, 303-308.	1.0	29
96	Class I HDAC imaging using [ <sup>3</sup> H]Cl-994 autoradiography. Epigenetics, 2013, 8, 756-764.	1.3	28
97	Reinvestigation of the synthesis and evaluation of [N-methyl-11C]vorozole, a radiotracer targeting cytochrome P450 aromatase. Nuclear Medicine and Biology, 2009, 36, 323-334.	0.3	27
98	Translation of HDAC6 PET Imaging Using [ <sup>18</sup> F]EKZ-001–cGMP Production and Measurement of HDAC6 Target Occupancy in Nonhuman Primates. ACS Chemical Neuroscience, 2020, 11, 1093-1101.	1.7	26
99	Metabolic Changes in the Rodent Brain after Acute Administration of Salvinorin A. Molecular Imaging and Biology, 2009, 11, 137-143.	1.3	25
100	<i>In Vivo</i> [ <sup>18</sup> F]GE-179 Brain Signal Does Not Show NMDA-Specific Modulation with Drug Challenges in Rodents and Nonhuman Primates. ACS Chemical Neuroscience, 2018, 9, 298-305.	1.7	25
101	The pandemic brain: Neuroinflammation in non-infected individuals during the COVID-19 pandemic. Brain, Behavior, and Immunity, 2022, 102, 89-97.	2.0	25
102	Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts. Journal of Pharmacology and Experimental Therapeutics, 2017, 361, 140-150.	1.3	24
103	Functionally Biased D2R Antagonists: Targeting the $\hat{l}^2$ -Arrestin Pathway to Improve Antipsychotic Treatment. ACS Chemical Biology, 2018, 13, 1038-1047.	1.6	24
104	Effects of flow changes on radiotracer binding: Simultaneous measurement of neuroreceptor binding and cerebral blood flow modulation. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 131-146.	2.4	24
105	Neuroimmune signatures in chronic low back pain subtypes. Brain, 2022, 145, 1098-1110.	3.7	24
106	Thalamic neuroinflammation as a reproducible and discriminating signature for chronic low back pain. Pain, 2021, 162, 1241-1249.	2.0	24
107	Reducing problems of cyclic trimer deposits in supercritical carbon dioxide polyester dyeing machinery. Journal of Supercritical Fluids, 2003, 26, 47-54.	1.6	23
108	PET Neuroimaging Studies of [ <sup>18</sup> F]CABS13 in a Double Transgenic Mouse Model of Alzheimer's Disease and Nonhuman Primates. ACS Chemical Neuroscience, 2015, 6, 535-541.	1.7	23

#	Article	IF	Citations
109	Epigenetics of Autism Spectrum Disorder: Histone Deacetylases. Biological Psychiatry, 2022, 91, 922-933.	0.7	23
110	Development of [ $<$ sup $>$ 18 $<$ /sup $>$ F]Maleimide-Based Glycogen Synthase Kinase-3 $\hat{l}^2$ Ligands for Positron Emission Tomography Imaging. ACS Medicinal Chemistry Letters, 2017, 8, 287-292.	1.3	22
111	Discrepancies in Kappa Opioid Agonist Binding Revealed through PET Imaging. ACS Chemical Neuroscience, 2019, 10, 384-395.	1.7	22
112	Moving Toward Multicenter Therapeutic Trials in Amyotrophic Lateral Sclerosis: Feasibility of Data Pooling Using Different Translocator Protein PET Radioligands. Journal of Nuclear Medicine, 2020, 61, 1621-1627.	2.8	22
113	Radiosynthesis and evaluation of [11C]EMPA as a potential PET tracer for orexin 2 receptors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3389-3392.	1.0	21
114	Synthesis and Evaluation of Methylated Arylazepine Compounds for PET Imaging of 5-HT <sub>2c</sub> Receptors. ACS Chemical Neuroscience, 2013, 4, 261-265.	1.7	21
115	PET Neurochemical Imaging Modes. Seminars in Nuclear Medicine, 2016, 46, 20-27.	2.5	21
116	Development of a Fluorinated Class-I HDAC Radiotracer Reveals Key Chemical Determinants of Brain Penetrance. ACS Chemical Neuroscience, 2016, 7, 528-533.	1.7	21
117	Positron Emission Tomography Assessment of the Intranasal Delivery Route for Orexin A. ACS Chemical Neuroscience, 2018, 9, 358-368.	1.7	21
118	Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial. NeuroImage: Clinical, 2021, 30, 102672.	1.4	21
119	An Efficient and Practical Radiosynthesis of [ <sup>11</sup> C]Temozolomide. Organic Letters, 2012, 14, 5872-5875.	2.4	20
120	Evaluation of potential PET imaging probes for the orexin 2 receptors. Nuclear Medicine and Biology, 2013, 40, 1000-1005.	0.3	19
121	Synthesis of [11C]SSR149415 and preliminary imaging studies using positron emission tomography. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3103-3106.	1.0	18
122	Radiosynthesis of Câ€11 labeled auxin (3â€indolyl[1â€ <sup>11</sup> C]acetic acid) and its derivatives from gramine. Journal of Labelled Compounds and Radiopharmaceuticals, 2011, 54, 433-437.	0.5	18
123	PET Imaging of Fatty Acid Amide Hydrolase with [ $<$ sup $>$ 18 $<$ /sup $>$ F]DOPP in Nonhuman Primates. Molecular Pharmaceutics, 2014, 11, 3832-3838.	2.3	18
124	Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 4, 29-38.	1.0	18
125	In vivo human brain expression of histone deacetylases in bipolar disorder. Translational Psychiatry, 2020, 10, 224.	2.4	17
126	The Role of Inflammation after Surgery for Elders (RISE) study: Examination of [11C]PBR28 binding and exploration of its link to post-operative delirium. NeuroImage: Clinical, 2020, 27, 102346.	1.4	17

#	Article	IF	CITATIONS
127	Functional Characterization of 5-HT <sub>1B</sub> Receptor Drugs in Nonhuman Primates Using Simultaneous PET-MR. Journal of Neuroscience, 2017, 37, 10671-10678.	1.7	16
128	Molecular and functional PET-fMRI measures of placebo analgesia in episodic migraine: Preliminary findings. NeuroImage: Clinical, 2018, 17, 680-690.	1.4	16
129	Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 596-611.	3.3	16
130	Classics in Neuroimaging: Imaging the Dopaminergic Pathway with PET. ACS Chemical Neuroscience, 2017, 8, 1817-1819.	1.7	15
131	Adamantane/Cucurbituril: A Potential Pretargeted Imaging Strategy in Immuno-PET. Molecular Imaging, 2018, 17, 153601211879983.	0.7	15
132	An efficient and practical synthesis of $[2-\langle \sup >11\langle \sup >C]$ indole via superfast nucleophilic $[\langle \sup >11\langle \sup >C]$ cyanation and RANEY® Nickel catalyzed reductive cyclization. Organic and Biomolecular Chemistry, 2015, 13, 11235-11243.	1.5	14
133	Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET. Neuropsychopharmacology, 2015, 40, 2865-2872.	2.8	14
134	Activity-dependent Regulation of Histone Lysine Demethylase KDM1A by a Putative Thiol/Disulfide Switch. Journal of Biological Chemistry, 2016, 291, 24756-24767.	1.6	14
135	Toward development of epigenetic drugs for central nervous system disorders: Modulating neuroplasticity <i>via</i> <scp>H3K4</scp> methylation. Psychiatry and Clinical Neurosciences, 2016, 70, 536-550.	1.0	14
136	FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors. Neuroscience Letters, 2013, 550, 119-124.	1.0	13
137	Tracing the History of the Human Translocator Protein to Recent Neurodegenerative and Psychiatric Imaging. ACS Chemical Neuroscience, 2020, 11, 2192-2200.	1.7	13
138	Evaluation of [11C]metergoline as a PET radiotracer for 5HTR in nonhuman primates. Bioorganic and Medicinal Chemistry, 2010, 18, 7739-7745.	1.4	12
139	Development of New Positron Emission Tomography Radiotracer for BET Imaging. ACS Chemical Neuroscience, 2017, 8, 17-21.	1.7	11
140	Metal Protein-Attenuating Compound for PET Neuroimaging: Synthesis and Preclinical Evaluation of [ <sup>11</sup> C]PBT2. Molecular Pharmaceutics, 2018, 15, 695-702.	2.3	11
141	The Role of Inflammation after Surgery for Elders (RISE) study: Study design, procedures, and cohort profile. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 752-762.	1.2	11
142	Effects of ferumoxytol on quantitative PET measurements in simultaneous PET/MR whole-body imaging: a pilot study in a baboon model. EJNMMI Physics, 2015, 2, 6.	1.3	10
143	Nasal neuron PET imaging quantifies neuron generation and degeneration. Journal of Clinical Investigation, 2017, 127, 681-694.	3.9	10
144	Radiolabelling and positron emission tomography of PT70, a time-dependent inhibitor of InhA, the Mycobacterium tuberculosis enoyl-ACP reductase. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4782-4786.	1.0	9

#	Article	IF	CITATIONS
145	A regularized full reference tissue model for PET neuroreceptor mapping. NeuroImage, 2016, 139, 405-414.	2.1	9
146	Class I and II histone deacetylase expression is not altered in human amyotrophic lateral sclerosis: Neuropathological and positron emission tomography molecular neuroimaging evidence. Muscle and Nerve, 2019, 60, 443-452.	1.0	9
147	Comparison of Two Clinical Upper Motor Neuron Burden Rating Scales in ALS Using Quantitative Brain Imaging. ACS Chemical Neuroscience, 2021, 12, 906-916.	1.7	9
148	Synthesis of N,N-diethyl-N-{4-[(E)-(4-nitrophenyl)diazenyl]phenyl}amine via in situ diazotisation and coupling in supercritical carbon dioxide. Coloration Technology, 2002, 118, 273-276.	0.7	8
149	Radiosynthesis and biological evaluation of a novel enoyl-ACP reductase inhibitor for Staphylococcus aureus. European Journal of Medicinal Chemistry, 2014, 88, 66-73.	2.6	8
150	Preclinical PET Neuroimaging of [ <sup>11</sup> C]Bexarotene. Molecular Imaging, 2016, 15, 153601211666305.	0.7	8
151	Beyond the Amyloid Hypothesis of Alzheimer's Disease: Tau Pathology Takes Center Stage. ACS Chemical Neuroscience, 2018, 9, 2519-2519.	1.7	8
152	Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. Neuro-Oncology Advances, 2020, 2, vdaa157.	0.4	8
153	Coevolution of Atomic Resolution and Whole-Brain Imaging for Tau Neurofibrillary Tangles. ACS Chemical Neuroscience, 2020, 11, 2513-2522.	1.7	8
154	CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models. Cancers, 2020, 12, 1922.	1.7	7
155	[11C]PR04.MZ, a promising DAT ligand for low concentration imaging: Synthesis, efficient 11C-O-methylation and initial small animal PET studies. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4343-4345.	1.0	6
156	Characterisation of [11C]PRO4.MZ in Papio anubis baboon: A selective high-affinity radioligand for quantitative imaging of the dopamine transporter. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 679-682.	1.0	6
157	A Chemical Strategy for the Cell-Based Detection of HDAC Activity. ACS Chemical Biology, 2014, 9, 1257-1262.	1.6	6
158	Imaging cardiac SCN5A using the novel F-18 radiotracer radiocaine. Scientific Reports, 2017, 7, 42136.	1.6	6
159	Design, construction and testing of a low-cost automated (68)Gallium-labeling synthesis unit for clinical use. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 176-84.	1.0	6
160	Specific <sup>18</sup> F-FDHT Accumulation in Human Prostate Cancer Xenograft Murine Models Is Facilitated by Prebinding to Sex Hormone–Binding Globulin. Journal of Nuclear Medicine, 2018, 59, 1538-1543.	2.8	5
161	Response to Comment on "ln Vivo [ <sup>18</sup> F]GE-179 Brain Signal Does Not Show NMDA-Specific Modulation with Drug Challenges in Rodents and Nonhuman Primates†ACS Chemical Neuroscience, 2019, 10, 773-775.	1.7	5
162	Synthesis, properties and application of four new 1;2 aluminium-complexed azo dyes. Coloration Technology, 2003, 119, 41-47.	0.7	4

#	Article	IF	CITATIONS
163	First D1-like receptor PET imaging of the rat and primate kidney: implications for human disease monitoring. American Journal of Physiology - Renal Physiology, 2014, 307, F116-F121.	1.3	4
164	Reply. Annals of Neurology, 2017, 81, 324-325.	2.8	4
165	FDA Approval of Aducanumab Divided the Community but Also Connected and United It. ACS Chemical Neuroscience, 2021, 12, 2716-2717.	1.7	4
166	Long-Term Effects of Repeated Blast Exposure in United States Special Operations Forces Personnel: A Pilot Study Protocol. Journal of Neurotrauma, 2022, 39, 1391-1407.	1.7	4
167	Radiosynthesis and preclinical evaluation of [ <sup>11</sup> C]Cimbiâ€701 – Towards the imaging of cerebral 5â€HT <sub>7</sub> receptors. Journal of Labelled Compounds and Radiopharmaceuticals, 2020, 63, 46-55.	0.5	3
168	A Baboon Brain Atlas for Magnetic Resonance Imaging and Positron Emission Tomography Image Analysis. Frontiers in Neuroanatomy, 2021, 15, 778769.	0.9	3
169	Editors' Favorites of 2017. ACS Chemical Neuroscience, 2018, 9, 1-4.	1.7	2
170	Giving Credit Where Credit Is Due: Properly Citing Relevant Prior Art. Journal of Medicinal Chemistry, 2021, 64, 5225-5225.	2.9	2
171	Imaging Epigenetics of Prenatal THC. ACS Chemical Neuroscience, 2021, 12, 1466-1468.	1.7	2
172	[ <sup>11</sup> C]PBR28 radiotracer kinetics are not driven by alterations in cerebral blood flow. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 3069-3084.	2.4	2
173	Discovery of Highly Potent Adenosine A1 Receptor Agonists: Targeting Positron Emission Tomography Probes. ACS Chemical Neuroscience, 2021, 12, 3410-3417.	1.7	2
174	Neuroinflammation: Brain on Fire?. ACS Chemical Neuroscience, 2016, 7, 415-415.	1.7	1
175	Editors' Favorites of 2016. ACS Chemical Neuroscience, 2017, 8, 1-3.	1.7	1
176	Time Will Tell the Utility of Biomarkers. ACS Chemical Neuroscience, 2020, 11, 1692-1695.	1.7	1
177	Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F]JNJ42259152 PET study in rats. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 492-502.	3.3	1
178	OUP accepted manuscript. Brain, 2022, , .	3.7	1
179	New Chemical Tools for Protein Modification. ChemInform, 2006, 37, no.	0.1	0
180	Noninvasive Determination of 2-[ <sup>18</sup> F]-Fluoroisonicotinic Acid Hydrazide Pharmacokinetics by Positron Emission Tomography in Mycobacterium tuberculosis-Infected Mice. Antimicrobial Agents and Chemotherapy, 2013, 57, 678-678.	1.4	0

#	Article	IF	CITATIONS
181	NIMG-29RADIOLABELED TEMOZOLOMIDE CAN MEASURE BEVACIZUMAB INDUCED VASCULAR MODULATION IN PATIENTS WITH RECURRENT GBM. Neuro-Oncology, 2015, 17, v160.1-v160.	0.6	0
182	NIMG-42. PENETRATION OF RADIOLABELED TEMOZOLOMIDE CORRELATES WITH CONTRAST ENHANCEMENT IN PATIENTS WITH RECURRENT GBM TREATED WITH BEVACIZUMAB. Neuro-Oncology, 2016, 18, vi133-vi133.	0.6	0
183	IC-P-166: Olfactory Sensory Neuron Monitoring in Alzheimer's Disease: Toward Human Translation of a Pet Imaging Agent. , 2016, 12, P122-P122.		0
184	Editors' Favorites: Best of 2018. ACS Chemical Neuroscience, 2019, 10, 1-4.	1.7	0
185	Giving Credit Where Credit Is Due: Properly Citing Relevant Prior Art. ACS Medicinal Chemistry Letters, 2021, 12, 669-669.	1.3	0
186	Giving Credit Where Credit Is Due: Properly Citing Relevant Prior Art. ACS Chemical Neuroscience, 2021, 12, 1465-1465.	1.7	0
187	Exploring Gender Differences in the Placebo Response to Major Depressive Disorder (MDD) Using Neuroimaging Techniques. Biological Psychiatry, 2021, 89, S171-S172.	0.7	0
188	A Reflection on Juneteenth and the Diversity of Our Chemical Neuroscience Community. ACS Chemical Neuroscience, 2021, 12, 2254-2255.	1.7	0
189	Chemical Neuroscience and the Paths to Impact. ACS Chemical Neuroscience, 2021, 12, 1-1.	1.7	0
190	Imaging the Distribution of Carbonâ€11 Labeled Rifampicin, Isoniazid and Pyrazinamide in Baboons using PET. FASEB Journal, 2010, 24, 907.7.	0.2	0